PFE
Pfizer Inc. NYSE Listed Jun 1, 1972$25.21
-2.74%
vs $25.92
Mkt Cap $143.3B
52w Low $23.29
36.5% of range
52w High $28.55
50d MA $26.25
200d MA $25.88
P/E (TTM)
18.5x
EV/EBITDA
12.7x
P/B
1.6x
Debt/Equity
0.8x
ROE
9.0%
P/FCF
15.8x
RSI (14)
37.30
ATR (14)
$0.46
Beta
0.39
50d MA
$26.25
200d MA
$25.88
Avg Volume
37.5M
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
66 Hudson Boulevard East · New York City, NY 10001-2192 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 0.72 | 0.75 | +3.9% | 26.45 | +0.4% | +0.3% | -0.2% | -3.0% | +0.5% | +0.2% | — |
| Feb 3, 2026 | TNS | 0.57 | 0.66 | +16.4% | 25.77 | +0.4% | +3.9% | +0.0% | -1.1% | +2.8% | -0.6% | — |
| Nov 4, 2025 | TNS | 0.63 | 0.87 | +37.4% | 24.30 | +0.3% | +1.3% | +0.0% | +1.0% | -1.7% | -0.2% | — |
| Aug 5, 2025 | TNS | 0.58 | 0.78 | +34.5% | 24.75 | -0.3% | -3.3% | +0.0% | +1.3% | +1.4% | +0.0% | — |
| Apr 29, 2025 | TNS | 0.67 | 0.92 | +38.1% | 23.79 | +1.7% | +2.6% | +0.0% | -2.0% | +1.1% | -1.4% | — |
| Feb 4, 2025 | TNS | 0.47 | 0.63 | +33.6% | 25.87 | +0.3% | +2.2% | +0.0% | -2.3% | -0.3% | +0.5% | — |
| Oct 29, 2024 | TNS | 0.61 | 1.06 | +72.6% | 28.46 | -0.5% | +0.2% | +0.0% | -0.8% | -0.7% | -1.2% | — |
| Jul 30, 2024 | TNS | 0.46 | 0.60 | +31.0% | 31.39 | -0.6% | -2.7% | +0.0% | +0.4% | -0.7% | -2.3% | — |
| May 1, 2024 | TNS | 0.52 | 0.82 | +58.9% | 27.18 | +0.1% | +1.9% | +0.0% | +0.4% | +1.3% | -1.4% | — |
| Jan 30, 2024 | TNS | -0.19 | 0.10 | +152.6% | 27.02 | +0.6% | +0.2% | +0.0% | +0.8% | -1.3% | -1.3% | — |
| Oct 31, 2023 | TNS | -0.32 | -0.17 | +46.9% | 30.56 | +0.0% | -0.2% | +0.0% | -0.0% | +2.5% | -0.3% | — |
| Aug 1, 2023 | TNS | 0.56 | 0.67 | +19.6% | 35.61 | +0.1% | -0.7% | +0.0% | -1.0% | +0.1% | +1.9% | — |
| May 2, 2023 | BMO | 0.98 | 1.23 | +25.5% | 39.06 | +0.4% | -1.6% | +0.0% | -0.6% | +0.7% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10 | RBC Capital Mkts | Upgrade | Underperform → Sector Perform | $25 | $25.70 | $25.80 | +0.4% | -0.4% | +2.2% | +0.2% | -0.8% | +0.2% |
| Apr 20 | RBC Capital | Maintains | Underperform → Underperform | — | $27.56 | $27.59 | +0.1% | -0.1% | -0.8% | -1.9% | -0.5% | +1.2% |
| Apr 13 | UBS | Maintains | Neutral → Neutral | — | $26.92 | $26.83 | -0.3% | +1.6% | -0.8% | +0.3% | +0.1% | +1.2% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.22 | $27.32 | +0.4% | -1.1% | +1.6% | -0.8% | +0.3% | +0.1% |
| Apr 9 | BofA Securities | Maintains | Neutral → Neutral | — | $27.47 | $27.21 | -0.9% | -0.9% | -1.1% | +1.6% | -0.8% | +0.3% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $26.77 | $26.60 | -0.6% | +0.7% | +1.2% | +1.1% | -1.9% | +2.7% |
| Mar 17 | HSBC | Maintains | Buy → Buy | — | $26.61 | $26.82 | +0.8% | +3.2% | -0.5% | +0.3% | -1.6% | -0.7% |
| Mar 2 | Argus | Upgrade | Hold → Buy | — | $27.65 | $27.57 | -0.3% | -1.4% | -2.5% | +0.2% | -0.0% | +1.7% |
| Feb 9 | Freedom Broker | Maintains | Buy → Buy | — | $27.22 | $27.18 | -0.1% | -0.6% | +2.1% | +0.4% | -0.9% | +0.4% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $25.77 | $25.88 | +0.4% | +3.9% | -1.1% | +2.8% | -0.6% | +2.1% |
| Jan 27 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $25.88 | $25.94 | +0.2% | +2.4% | -2.4% | +0.9% | +1.3% | +0.8% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.53 | $25.40 | -0.5% | -1.9% | +0.0% | +0.6% | +0.1% | -1.3% |
| Dec 15 | BofA Securities | Maintains | Neutral → Neutral | — | $25.85 | $25.82 | -0.1% | +2.2% | -3.4% | -1.9% | +0.0% | +0.6% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.80 | $25.84 | +0.2% | +0.2% | +2.2% | -3.4% | -1.9% | +0.0% |
| Nov 24 | Guggenheim | Maintains | Buy → Buy | — | $25.04 | $25.11 | +0.3% | +0.7% | +2.0% | -0.0% | +0.1% | -1.8% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.24 | $25.26 | +0.1% | -1.8% | -0.2% | -0.8% | -0.5% | -0.7% |
| Oct 3 | BofA Securities | Maintains | Neutral → Neutral | — | $27.08 | $27.20 | +0.4% | +1.1% | -3.4% | -0.6% | -2.2% | -1.7% |
| Aug 6 | BofA Securities | Maintains | Neutral → Neutral | — | $24.75 | $24.68 | -0.3% | -3.3% | +1.3% | +1.4% | +0.0% | +0.3% |
| Aug 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $24.75 | $24.68 | -0.3% | -3.3% | +1.3% | +1.4% | +0.0% | +0.3% |
| Aug 6 | Citigroup | Maintains | Neutral → Neutral | — | $24.75 | $24.68 | -0.3% | -3.3% | +1.3% | +1.4% | +0.0% | +0.3% |
| Apr 30 | UBS | Maintains | Neutral → Neutral | — | $23.79 | $24.20 | +1.7% | +2.6% | -2.0% | +1.1% | -1.4% | -4.1% |
| Apr 8 | UBS | Maintains | Neutral → Neutral | — | $22.63 | $22.90 | +1.2% | -3.5% | +3.0% | -4.0% | +1.5% | +1.0% |
| Apr 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $22.63 | $22.90 | +1.2% | -3.5% | +3.0% | -4.0% | +1.5% | +1.0% |
| Mar 18 | Guggenheim | Maintains | Buy → Buy | — | $26.05 | $26.21 | +0.6% | +1.0% | -0.4% | -0.1% | +0.3% | -0.5% |
| Mar 12 | Guggenheim | Maintains | Buy → Buy | — | $25.99 | $25.94 | -0.2% | -1.1% | -0.4% | +0.5% | +1.3% | +1.0% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $25.74 | $25.78 | +0.2% | +0.5% | -1.3% | -0.2% | +0.7% | -0.4% |
| Feb 5 | UBS | Maintains | Neutral → Neutral | — | $25.87 | $25.95 | +0.3% | +2.2% | -2.3% | -0.3% | +0.5% | -1.3% |
| Jan 28 | Citigroup | Maintains | Neutral → Neutral | — | $26.86 | $26.78 | -0.3% | -0.4% | -0.5% | +1.1% | -1.4% | -1.2% |
| Jan 8 | UBS | Maintains | Neutral → Neutral | — | $27.13 | $27.05 | -0.3% | -1.0% | -0.5% | +0.3% | -1.5% | -0.7% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $26.43 | $26.19 | -0.9% | -2.0% | -0.5% | +2.3% | +1.3% | +0.1% |
| Dec 11 | Guggenheim | Maintains | Buy → Buy | — | $25.57 | $25.38 | -0.7% | -1.3% | +0.6% | +0.8% | -1.3% | +4.7% |
| Oct 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $28.46 | $28.31 | -0.5% | +0.2% | -0.8% | -0.7% | -1.2% | +0.8% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.64 | $28.68 | +0.1% | -0.7% | +1.4% | -1.4% | +0.2% | -0.8% |
| Oct 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.84 | $28.87 | +0.1% | +0.1% | -0.8% | -0.7% | +1.4% | -1.4% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.34 | $29.36 | +0.1% | -0.6% | -0.3% | +1.2% | +0.8% | -1.3% |
| Oct 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.61 | $28.50 | -0.4% | -0.9% | +0.8% | +2.2% | -0.1% | +3.5% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $29.27 | $29.57 | +1.0% | +2.7% | -0.8% | -0.3% | -0.3% | -0.8% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.56 | $28.54 | -0.1% | +3.0% | +1.1% | -0.3% | -1.7% | +0.4% |
| Aug 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.30 | $28.35 | +0.2% | +1.8% | +0.3% | +0.4% | -0.9% | +0.4% |
| Aug 8 | Daiwa Capital | Upgrade | Neutral → Outperform | — | $28.85 | $28.93 | +0.3% | -0.3% | -0.7% | -0.4% | +1.4% | +0.1% |
| Jul 31 | UBS | Maintains | Neutral → Neutral | — | $31.39 | $31.20 | -0.6% | -2.7% | +0.4% | -0.7% | -2.3% | -1.4% |
| Jul 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $31.39 | $31.20 | -0.6% | -2.7% | +0.4% | -0.7% | -2.3% | -1.4% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $31.39 | $31.20 | -0.6% | -2.7% | +0.4% | -0.7% | -2.3% | -1.4% |
| Jul 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.39 | $31.20 | -0.6% | -2.7% | +0.4% | -0.7% | -2.3% | -1.4% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.72 | $27.83 | +0.4% | +2.3% | +1.1% | +0.9% | +0.6% | +1.4% |
| Jul 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $27.72 | $27.83 | +0.4% | +2.3% | +1.1% | +0.9% | +0.6% | +1.4% |
| Jul 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.98 | $27.95 | -0.1% | +0.9% | -1.4% | -0.5% | +1.3% | -0.4% |
| Jun 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.99 | $27.91 | -0.3% | -2.0% | +1.4% | +0.6% | +0.9% | -1.4% |
| Jun 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.41 | $27.20 | -0.8% | +1.2% | +0.0% | +2.2% | -1.3% | -2.0% |
| Jun 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.53 | $27.45 | -0.3% | -2.0% | +1.6% | +1.2% | +0.0% | +2.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | DAMICO JENNIFER B.Off | SVP & Controller | Sell | 2,000 | $25.70 | $51K | 31,397 | +2.23% | -0.46% |
8-K · 5.02
!!! Very High
Pfizer Inc. -- 8-K 5.02: Executive Change
Jun 18
8-K · 7.01
! Medium
Pfizer Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 18
8-K · 2.02
!! High
Pfizer Inc. -- 8-K 2.02: Earnings Results
Pfizer reported first-quarter 2026 earnings on May 5, 2026, with results now available for investor review to assess the pharmaceutical giant's operational performance and guidance outlook.
May 5
8-K
Pfizer Inc. -- 8-K Filing
Apr 27
8-K
Pfizer Inc. -- 8-K Filing
Pfizer reaffirmed its 2026 financial guidance, indicating management confidence in its forward outlook despite reporting Q4 and full-year 2025 results.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 369,430,012 | $10.4B | New | Mar 2026 |
| 2 | Morgan Stanley | 178,227,208 | $4.4B | Added | Dec 2025 |
| 3 | Vanguard Portfolio Management Llc | 116,734,695 | $3.3B | New | Mar 2026 |
| 4 | Northern Trust Corp | 62,026,552 | $1.7B | Reduced | Mar 2026 |
| 5 | State Farm Mutual Automobile Insurance Co | 54,508,560 | $1.5B | — | Mar 2026 |
| 6 | Bank Of New York Mellon Corp | 53,879,900 | $1.5B | Added | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 46,545,479 | $1.3B | Added | Mar 2026 |
| 8 | Amundi | 40,825,470 | $1.1B | New | Mar 2026 |
| 9 | Royal Bank Of Canada | 34,155,840 | $959M | Reduced | Mar 2026 |
| 10 | Franklin Resources Inc | 28,341,834 | $796M | Added | Mar 2026 |
| 11 | Invesco Ltd. | 27,941,976 | $785M | Added | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 27,894,042 | $775M | Added | Mar 2026 |
| 13 | Capital World Investors | 21,947,486 | $616M | Added | Mar 2026 |
| 14 | First Trust Advisors Lp | 20,422,958 | $573M | Added | Mar 2026 |
| 15 | Wells Fargo & Company/mn | 19,533,309 | $548M | New | Mar 2026 |
| 16 | Ubs Group Ag | 17,609,150 | $494M | Added | Mar 2026 |
| 17 | Marshall Wace, Llp | 16,082,788 | $452M | Added | Mar 2026 |
| 18 | Victory Capital Management Inc | 15,508,999 | $435M | Reduced | Mar 2026 |
| 19 | Barclays Plc | 14,689,187 | $412M | Reduced | Mar 2026 |
| 20 | National Pension Service | 14,349,288 | $403M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$143.34B
Enterprise Value
$191.39B
P/E (TTM)
18.54x
Forward P/E
8.52x
PEG Ratio
-4.31x
P/B
1.65x
P/S
2.29x
P/FCF
15.79x
EV/EBITDA
12.68x
Shares Out
5.69B
Financials (TTM)
Revenue
$62.58B
Net Income
$7.77B
EBITDA
$15.10B
Free Cash Flow
$9.08B
Op Cash Flow
$11.71B
EPS Basic
$1.36
EPS Diluted
$1.36
EPS Forward
$2.96
Gross Margin
70.3%
Op Margin
24.7%
Net Margin
12.4%
Balance Sheet
Total Assets
$208.16B
Total Liab.
$121.39B
Total Equity
$86.78B
Cash
$13.60B
LT Debt
$61.64B
Book Value/Sh
$15.27
Debt/Equity
0.78x
Current Ratio
1.16
Quick Ratio
0.87
Returns & Growth
ROE
9.0%
ROA
3.7%
ROIC
8.8%
Rev Growth YoY
-1.7%
EPS Growth YoY
-4.2%
Price Returns
2W
+1.7%
1M
-2.0%
3M
-5.4%
6M
+1.7%
12M
+11.4%
Technicals
52W High
$28.55
52W Low
$23.29
50d MA
$26.25
200d MA
$25.88
RSI (14)
37.30
ATR (14)
$0.46
Beta
0.39
Avg Volume
37.5M
Dividends
Div Rate
$1.72
Div Yield
6.5%
Frequency
4
Ex-Div Date
May 8, 2026
Analyst Price Targets
Consensus
$27.50
High
$35.00
Low
$24.00
Median
$27.00
Data updated apr 26, 2026 7:21pm
· Source: financialmodelingprep.com